Cargando…

Investigating the Anti-Inflammatory Effects of RCI001 for Treating Ocular Surface Diseases: Insight Into the Mechanism of Action

The ocular surface is continuously exposed to various environmental factors, and innate and adaptive immunity play crucial roles in ocular surface diseases (OSDs). Previously, we have reported that the topical application of RCI001 affords excellent anti-inflammatory and antioxidant effects in dry e...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seunghoon, Jang, Ye Won, Ku, Young-ah, Shin, Yungyeong, Rahman, Md Mahbubur, Chung, Myung-Hee, Kim, Yong Ho, Kim, Dong Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987014/
https://www.ncbi.nlm.nih.gov/pubmed/35401555
http://dx.doi.org/10.3389/fimmu.2022.850287
_version_ 1784682643579731968
author Kim, Seunghoon
Jang, Ye Won
Ku, Young-ah
Shin, Yungyeong
Rahman, Md Mahbubur
Chung, Myung-Hee
Kim, Yong Ho
Kim, Dong Hyun
author_facet Kim, Seunghoon
Jang, Ye Won
Ku, Young-ah
Shin, Yungyeong
Rahman, Md Mahbubur
Chung, Myung-Hee
Kim, Yong Ho
Kim, Dong Hyun
author_sort Kim, Seunghoon
collection PubMed
description The ocular surface is continuously exposed to various environmental factors, and innate and adaptive immunity play crucial roles in ocular surface diseases (OSDs). Previously, we have reported that the topical application of RCI001 affords excellent anti-inflammatory and antioxidant effects in dry eye disease and ocular chemical burn models. In this study, we examined the inhibitory effects of RCI001 on the Rac1 and NLRP3 inflammasomes in vitro and in vivo. Following RCI001 application to RAW264.7 and Swiss 3T3 cells, we measured Rac1 activity using a glutathione-S-transferase (GST) pull-down assay and G-protein activation assay kit. In addition, we quantified the expression of inflammatory cytokines (interleukin [IL]-1β, IL-6, and tumor necrosis factor [TNF]-α) in lipopolysaccharide (LPS)-stimulated RAW264.7 cells using ELISA and real-time PCR. In the mouse ocular alkali burn model, RCI001 was administered via eye drops (10 mg/mL, twice daily) for 5 days, and 1% prednisolone acetate (PDE) ophthalmic suspension was used as a positive control. Corneal epithelial integrity (on days 0-5) and histological examinations were performed, and transcript and protein levels of Rac1, NLRP3, caspase-1, and IL-1β were quantified using real-time PCR and western blotting in corneal tissues collected on days 3 and 5. We observed that RCI001 dose-dependently inhibited Rac1 activity and various inflammatory cytokines in LPS-stimulated murine macrophages. Furthermore, RCI001 restored corneal epithelial integrity more rapidly than corticosteroid treatment in chemically injured corneas. Compared to the saline group, activation of Rac1 and the NLRP3 inflammasome/IL-1β axis was suppressed in the RCI001 group, especially during the early phase of the ocular alkali burn model. Topical RCI001 suppressed the expression of activated Rac1 and inflammatory cytokines in vitro and rapidly restored the injured cornea by inhibiting activation of Rac1 and the NLRP inflammasome/IL-1β axis in vivo. Accordingly, RCI001 could be a promising therapeutic agent for treating OSDs.
format Online
Article
Text
id pubmed-8987014
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89870142022-04-08 Investigating the Anti-Inflammatory Effects of RCI001 for Treating Ocular Surface Diseases: Insight Into the Mechanism of Action Kim, Seunghoon Jang, Ye Won Ku, Young-ah Shin, Yungyeong Rahman, Md Mahbubur Chung, Myung-Hee Kim, Yong Ho Kim, Dong Hyun Front Immunol Immunology The ocular surface is continuously exposed to various environmental factors, and innate and adaptive immunity play crucial roles in ocular surface diseases (OSDs). Previously, we have reported that the topical application of RCI001 affords excellent anti-inflammatory and antioxidant effects in dry eye disease and ocular chemical burn models. In this study, we examined the inhibitory effects of RCI001 on the Rac1 and NLRP3 inflammasomes in vitro and in vivo. Following RCI001 application to RAW264.7 and Swiss 3T3 cells, we measured Rac1 activity using a glutathione-S-transferase (GST) pull-down assay and G-protein activation assay kit. In addition, we quantified the expression of inflammatory cytokines (interleukin [IL]-1β, IL-6, and tumor necrosis factor [TNF]-α) in lipopolysaccharide (LPS)-stimulated RAW264.7 cells using ELISA and real-time PCR. In the mouse ocular alkali burn model, RCI001 was administered via eye drops (10 mg/mL, twice daily) for 5 days, and 1% prednisolone acetate (PDE) ophthalmic suspension was used as a positive control. Corneal epithelial integrity (on days 0-5) and histological examinations were performed, and transcript and protein levels of Rac1, NLRP3, caspase-1, and IL-1β were quantified using real-time PCR and western blotting in corneal tissues collected on days 3 and 5. We observed that RCI001 dose-dependently inhibited Rac1 activity and various inflammatory cytokines in LPS-stimulated murine macrophages. Furthermore, RCI001 restored corneal epithelial integrity more rapidly than corticosteroid treatment in chemically injured corneas. Compared to the saline group, activation of Rac1 and the NLRP3 inflammasome/IL-1β axis was suppressed in the RCI001 group, especially during the early phase of the ocular alkali burn model. Topical RCI001 suppressed the expression of activated Rac1 and inflammatory cytokines in vitro and rapidly restored the injured cornea by inhibiting activation of Rac1 and the NLRP inflammasome/IL-1β axis in vivo. Accordingly, RCI001 could be a promising therapeutic agent for treating OSDs. Frontiers Media S.A. 2022-03-24 /pmc/articles/PMC8987014/ /pubmed/35401555 http://dx.doi.org/10.3389/fimmu.2022.850287 Text en Copyright © 2022 Kim, Jang, Ku, Shin, Rahman, Chung, Kim and Kim https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Kim, Seunghoon
Jang, Ye Won
Ku, Young-ah
Shin, Yungyeong
Rahman, Md Mahbubur
Chung, Myung-Hee
Kim, Yong Ho
Kim, Dong Hyun
Investigating the Anti-Inflammatory Effects of RCI001 for Treating Ocular Surface Diseases: Insight Into the Mechanism of Action
title Investigating the Anti-Inflammatory Effects of RCI001 for Treating Ocular Surface Diseases: Insight Into the Mechanism of Action
title_full Investigating the Anti-Inflammatory Effects of RCI001 for Treating Ocular Surface Diseases: Insight Into the Mechanism of Action
title_fullStr Investigating the Anti-Inflammatory Effects of RCI001 for Treating Ocular Surface Diseases: Insight Into the Mechanism of Action
title_full_unstemmed Investigating the Anti-Inflammatory Effects of RCI001 for Treating Ocular Surface Diseases: Insight Into the Mechanism of Action
title_short Investigating the Anti-Inflammatory Effects of RCI001 for Treating Ocular Surface Diseases: Insight Into the Mechanism of Action
title_sort investigating the anti-inflammatory effects of rci001 for treating ocular surface diseases: insight into the mechanism of action
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987014/
https://www.ncbi.nlm.nih.gov/pubmed/35401555
http://dx.doi.org/10.3389/fimmu.2022.850287
work_keys_str_mv AT kimseunghoon investigatingtheantiinflammatoryeffectsofrci001fortreatingocularsurfacediseasesinsightintothemechanismofaction
AT jangyewon investigatingtheantiinflammatoryeffectsofrci001fortreatingocularsurfacediseasesinsightintothemechanismofaction
AT kuyoungah investigatingtheantiinflammatoryeffectsofrci001fortreatingocularsurfacediseasesinsightintothemechanismofaction
AT shinyungyeong investigatingtheantiinflammatoryeffectsofrci001fortreatingocularsurfacediseasesinsightintothemechanismofaction
AT rahmanmdmahbubur investigatingtheantiinflammatoryeffectsofrci001fortreatingocularsurfacediseasesinsightintothemechanismofaction
AT chungmyunghee investigatingtheantiinflammatoryeffectsofrci001fortreatingocularsurfacediseasesinsightintothemechanismofaction
AT kimyongho investigatingtheantiinflammatoryeffectsofrci001fortreatingocularsurfacediseasesinsightintothemechanismofaction
AT kimdonghyun investigatingtheantiinflammatoryeffectsofrci001fortreatingocularsurfacediseasesinsightintothemechanismofaction